Ozempic won an FDA nod in January to reduce the risk of CV events in patients with Type 2 diabetes and established CV disease. (Novo Nordisk)
Ozempic Company: Novo Nordisk Used for: Glycemic control in adults with Type 2 diabetes 2019 sales: $1.64 billion
Novo Nordisk's 2019 was defined by its dogged pursuit of an FDA approval for Rybelsus (oral semaglutide), a next-gen GLP-1 drug with major blockbuster hopes. But the injectable form of the drug, Ozempic, continued its own march into blockbusterland last year—and those good times could continue.
This year, Ozempic could add a little more than $1 billion to its 2019 tally of $1.64 billion, EvaluatePharma said. That would bring Ozempic's 2020 sales up to $2.64 billion.
Riding on the strength of its weekly dosing, in comparison to other GLP-1 meds taken once a day, Ozempic jumped into the blockbuster ranks in 2019. But with a major FDA label expansion in January—to reduce cardiovascular risks in patients with Type 2 diabetes and known CV disease—those booming sales could be just the beginning.